04.14.14
Peter Steiger, Ph.D., has been appointed to the newly created position of vice president and chief scientific officer for Medical Imaging at PAREXEL. Dr. Steiger has more than 25 years of experience in specialized medical imaging techniques to support drug development. He will oversee the worldwide medical imaging scientific strategy at PAREXEL Informatics, which provides technology solutions to help facilitate the clinical development process.
Prior to joining the company, Dr. Steiger was chief executive officer of Optasia Medical from 2006 to 2013 and chief executive officer of Synarc from 2000 to 2005. He also served as chief scientist for Hologic, where he led the medical data management division responsible for supporting the use of bone densitometry measurements in clinical studies.
"Peter Steiger's proven industry track record and deep musculoskeletal imaging expertise make him an outstanding addition to our medical imaging team," said Xavier Flinois, president of PAREXEL Informatics. "Clinical study sponsors increasingly rely on medical imaging technologies as surrogate endpoints to quickly assess safety and efficacy for 'go/no-go' pipeline decision-making. Peter's appointment reflects our ongoing commitment to leveraging global industry expertise to advance our client's innovative pipelines and fully support them through their complex drug development journey."
Prior to joining the company, Dr. Steiger was chief executive officer of Optasia Medical from 2006 to 2013 and chief executive officer of Synarc from 2000 to 2005. He also served as chief scientist for Hologic, where he led the medical data management division responsible for supporting the use of bone densitometry measurements in clinical studies.
"Peter Steiger's proven industry track record and deep musculoskeletal imaging expertise make him an outstanding addition to our medical imaging team," said Xavier Flinois, president of PAREXEL Informatics. "Clinical study sponsors increasingly rely on medical imaging technologies as surrogate endpoints to quickly assess safety and efficacy for 'go/no-go' pipeline decision-making. Peter's appointment reflects our ongoing commitment to leveraging global industry expertise to advance our client's innovative pipelines and fully support them through their complex drug development journey."